CA
NVCR icon

Cetera Advisors’s NovoCure NVCR Stock Holding History

Cetera Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,816
Closed -$403K – 1455
2021
Q2 		$403K Hold
1,816
– – 0.01% 916
2021
Q1 		$240K Sell
1,816
-260
-13% -$41.1K 0.01% 1059
2020
Q4 		$359K Hold
2,076
– – 0.01% 762
2020
Q3 		$231K Buy
+2,076
New +$166K 0.01% 832

Other funds holding NVCR

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cetera Advisors's NVCR Position: Q3 2021 in Review

Cetera Advisors sold out of NovoCure (NVCR) in Q3 2021, closing a stake of 1,816 shares — an estimated $403K sold.

Cetera Advisors first reported a position in NVCR in Q3 2020 and held it in 4 quarters. The position peaked at $403K in Q2 2021. 317 funds tracked by Wall St. Rank hold NVCR as of Q3 2021.

  • Cetera Advisors reported no remaining NovoCure position as of Q3 2021 after selling out during the quarter.
  • Cetera Advisors sold 1,816 NovoCure shares in Q3 2021, an estimated $403K.
  • Cetera Advisors first reported a position in NovoCure in Q3 2020 and held it in 4 quarters.
  • Cetera Advisors's NovoCure position peaked at $403K in Q2 2021.
  • 317 funds tracked by Wall St. Rank held NovoCure as of Q3 2021.

Based on Cetera Advisors's 13F filing for Q3 2021, filed 16 Nov 2021.